New comorbidity tool predicts risk of hospitalisation and death in psoriatic arthriti

London, United Kingdom, June 9, 2016: The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2016) showed that a newly developed method of evaluating the impact of different comorbidities in patients with Psoriatic Arthritis (PsA) can be used to prospectively identify those PsA patients at greater risk of hospitalisation and premature death. In addition to helping predict the future use of resources and identify targets to reduce costs, application of this new PsA-comorbidity index may ultimately improve outcomes for PsA patients.

"To date, no disease-specific models had been developed to identify those comorbidities with the greatest impact on PsA patients' health status," said Dr Yasser El Miedany of the Department of Rheumatology, Darent Valley Hospital, UK. "We have now developed and validated a PsA-comorbidity index (PsACI), which will enable clinicians to prospectively include comorbidities assessment and management in their standard practice.

"Once our research has been published, we suggest this new tool is included as part of the patient-reported outcome measures used in standard clinical practice. By making PsACI available to rheumatologists worldwide, we hope it will prove an effective guide to optimising the management of Psoriatic Arthritis," Dr Yasser El Miedany concluded.

PsA, an inflammatory arthritis associated with joint pain and swelling which can lead to joint damage and long-term disability, is a common complication of psoriasis. Psoriasis occurs in 1-3% of the population, and the estimated prevalence of PsA among psoriasis patients varies widely from 6-42%, due to heterogeneity in study methods and the lack of widely accepted classification or diagnosis criteria. Due to dual skin and joint involvement, patients with PsA experience further impairment and consequently a lower quality of life compared with patients with psoriasis alone.

which increases with the severity of the psoriasis and with the presence of severe PsA, increases mortality.2

A retrospective multicentre analysis of 1,707 PsA patients, monitored over a 10-year period, assessed the impact of different comorbidities on predicting future death and hospitalisation. To develop a morbidity index score, different cut-off values were identified to delineate patients at different stages of risk of hospitalisation and death.

Those PsA patients who had a higher incidence of comorbid conditions and were at higher risk of hospitalisation were men, with older age at disease onset, and a high BMI at baseline (p < 0.05). The most prevalent comorbidities strongly associated with a 10-year risk of death or hospitalisation in PsA patients were: cardiovascular (seven different comorbidities), osteoporosis, falls, depression / anxiety, diabetes mellitus, renal and liver diseases, lung and GI problems, as well as infection (p < 0.001).

A Multidimensional Disease Severity score as an independent predictor of disease status (based on 5 different indicators of disease activity (DAPSA, PASI , Functional disability score, enthesitis and ESR /CRP ) was shown to be significantly associated with the 10-year risk of death or hospitalisation (p=0.002). Male gender, cardiovascular disease, evidence of a risk of falls, diabetes, infection, anxiety, and this MDR score were all significant independent factors affecting the outcome of the disease at 10 years.

The PsA comorbidity index weighted according to analysis of the above variables produced a score that ranged from 0 to 36, with a cut-off point of 14.5 associated with a sensitivity of 97.5% and a specificity of 87%.

Abstract Number: OP0091

###

NOTES TO EDITORS:

For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress

Press Office in the London Suite at ExCel London during EULAR 2016 or on:

The European League Against Rheumatism (EULAR) is an umbrella organisation which represents scientific societies, health professional associations and organisations for people with Rheumatic Musculoskeletal Diseases (RMD) throughout Europe.

EULAR aims to promote, stimulate and support the research, prevention, and treatment of RMD and the rehabilitation of those it affects.

EULAR underlines the importance of combating rheumatic diseases not only by medical means, but also through a wider context of care for rheumatic patients and a thorough understanding of their social and other needs. EULAR is supported in this mission by its 45 scientific member societies, 36 PARE (People with Arthritis/Rheumatism in Europe) organisations, 22 HPR (Health Professionals in Rheumatology) associations and 23 corporate members.

The EULAR Annual European Congress of Rheumatology is the foremost international medical meeting announcing the latest research on rheumatic and musculoskeletal diseases. EULAR 2016 is expected to attract over 14,000 delegates from around 120 countries. Most if not all professions working in the vast field of RMD will be represented.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.